Sanofi Poised for Swift Medivation Move as Earnings Drop

  • Second-quarter profit drops 8.7% as Plavix, Lantus decline
  • Drugmaker maintains forecast for stable earnings in 2016

Sanofi said it’s ready to act swiftly to reach a deal with U.S. biotechnology company Medivation Inc. as profit and sales declined, highlighting the need for new medicines to propel growth.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.